Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL

Summary

This prospective study will be conducted in high-risk B-ALL patients post-allo-HSCT. We propose to investigate the safety and therapeutic efficacy of blinatumomab plus low-dose DLI maintenance therapy, with the ultimate goal of enhancing long-term survival outcomes.

Timeline

Start

2024-12-01

Primary completion

2028-11-30

Completion

2028-12-01

Drugs

Indications